Patents Examined by Nancy J Leith
  • Patent number: 11680259
    Abstract: This invention relates to recombinant Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) arrays and recombinant nucleic acid constructs encoding Type I-E CASCADE complexes as well as plasmids, retroviruses and bacteriophage comprising the same.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: June 20, 2023
    Assignee: North Carolina State University
    Inventors: Rodolphe Barrangou, Claudio Hidalgo-Cantabrana
  • Patent number: 11674155
    Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: June 13, 2023
    Assignee: CELLECTIS
    Inventors: Jean-Pierre Cabaniols, Jean-Charles Epinat, Philippe Duchateau
  • Patent number: 11667933
    Abstract: The invention relates to a method comprising a) providing a host cell said host cell comprising an episomal replicon, said episomal replicon comprising a donor nucleic acid sequence, said host cell further comprising a target nucleic acid, b) providing helper protein(s) capable of supporting nucleic acid recombination in said host cell c) providing helper protein(s) and/or RNAs capable of supporting nucleic acid excision in said host cell wherein said donor nucleic acid sequence comprises in order. 5?-homologous recombination sequence 1-sequence of interest-homologous recombination sequence 2-3? wherein said sequence of interest comprises a positive selectable marker d) inducing excision of said donor nucleic acid sequence e) incubating to allow recombination between the excised donor nucleic acid and said target nucleic acid f) selecting for recombinants having incorporated said donor nucleic acid into said target nucleic acid. Also described are nucleic acids and cells.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: June 6, 2023
    Inventors: Julius Fredens, Kaihang Wang, Jason W. Chin
  • Patent number: 11667911
    Abstract: The present disclosure is directed to methods of producing a modified nucleic acid comprising a precise deletion in a target nucleic acid in a cell comprising generating, within the cell, a first single strand break on a first strand of the target nucleic acid and a second single strand break on a second strand of the target nucleic acid, thereby forming a double strand break in the target nucleic acid having a first 3? overhang and a second 3? overhang; processing the first 3? overhang and the second 3? overhang with an exonuclease molecule, thereby deleting the segment of the target nucleic acid that was located between the first single strand break and the second single strand break, and forming a processed double strand break; and allowing the processed double strand break to be repaired by at least one DNA repair pathway, thereby producing the modified nucleic acid comprising the precise deletion in the target nucleic acid in the cell.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: June 6, 2023
    Assignee: Editas Medicine, Inc.
    Inventors: Anne Helen Bothmer, Cecilia Cotta-Ramusino, Luis A. Barrera
  • Patent number: 11661589
    Abstract: Provided are modified microorganisms which are modified such that their growth can be controlled using exogenously provided compounds. The microorganisms can be modified by genetic alterations that include a promoter inducible by a first exogenously supplied compound. The promoter can be configured to drive expression of an RNA coding sequence that may be essential to growth of the microorganism. The microorganisms may also be modified to include site specific recombinase recognition sites flanking or within the RNA coding sequence so that expression of the corresponding site specific recombinase will disrupt transcription of the RNA. The site specific recombinase can be configured such that it expression and/or activity is suppressed by a second exogenously supplied compound. Methods of making the modified microorganisms and kits that contain reagents for making and using the modified microorganisms are also provided.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: May 30, 2023
    Assignees: New York University, The Johns Hopkins University
    Inventors: Jef D. Boeke, Neta Agmon, Yizhi Cai
  • Patent number: 11661612
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: May 30, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
  • Patent number: 11647753
    Abstract: Compositions and methods for efficiently producing and delivering double stranded RNA (dsRNA) are provided. Vector constructs useful for in vitro and in vivo expression of dsRNA are described. Also described are cell expression systems for efficient and cost-effective production of dsRNA in living cells and methods and compositions for providing the expressed dsRNA to target organisms. The described compositions and methods can be used to produce RNA molecules for screening or other uses, and to amplify RNA sequences for analysis.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: May 16, 2023
    Assignee: Monsanto Technology LLC
    Inventors: James A. Baum, Allen T. Christian, Artem Evdokimov, Farhad Moshiri, Lisa Marie Weaver, Haitao Zhang
  • Patent number: 11649474
    Abstract: Disclosed is a method for producing a glycoprotein using mammalian cells, wherein all or part of the non-reducing ends of N-glycoside binding sugar chains are mannose residues. The method is a method for producing glycoproteins using transformant mammalian cells which are prepared by introducing thereinto a ?-N-acetylglucosaminidase gene and inducing its expression.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: May 16, 2023
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventor: Kenichi Takahashi
  • Patent number: 11643669
    Abstract: The present invention relates to systems and methods for recording and assaying cellular events, in particular gene expression. The invention provides hereto a method of determining a cellular event of interest in a cell comprising providing a cell comprising a CRISPR-Cas system, wherein the CRISPR-Cas system comprises a guide RNA that targets a selected DNA sequence and a Cas protein capable of modifying the selected DNA sequence; whereby a nucleic acid molecule encoding at least one of the guide RNA or Cas protein is operably connected in the cell with a regulatory element comprising a promoter responsive to the cellular event, and whereby expression of at least one CRISPR-Cas system component is driven by the promoter; and determining cellular event of interest based on detection of the modification of the selected DNA sequence.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: May 9, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Alexander K. Shalek, Alethe Gaillard De Saint Germain
  • Patent number: 11639511
    Abstract: Described herein are molecules for editing a cell. The molecules described herein generally comprise the following covalently-linked components and a nucleic acid encoding a guide RNA (gRNA) sequence targeting a target region in a cell and a region homologous to the target region comprising a change in sequence relative to the target region.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: May 2, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Andrew Garst, Ryan T Gill
  • Patent number: 11634755
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: April 25, 2023
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TEOHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Feng Zhang, Bernd Zetsche, Johnathan S. Gootenberg, Omar O. Abudayyeh, Ian Slaymaker
  • Patent number: 11634719
    Abstract: The present disclosure provides automated multi-module instrumentation and automated methods for performing recursive editing of live cells with curing of editing vectors from prior rounds of editing.
    Type: Grant
    Filed: February 20, 2022
    Date of Patent: April 25, 2023
    Assignee: Inscripta, Inc.
    Inventors: Charles Johnson, Tian Tian, Eileen Spindler
  • Patent number: 11624069
    Abstract: Provided is an in vitro method for making a recombinant DNA molecule. The method includes combining in vitro a recombination-site-mediated evolution (a SCRaMbLE) ready DNA polynucleotide that contains at least one transcription unit (TU) and an introduced site-specific recombinase recognition sites that can be recognized by a recombinase, with a recombinase that recognizes the site-specific recombinase recognition sites. The method results in a polynucleotide that is recombined to provide a recombined polynucleotide. The method may further include determining the sequence, or determining the expression of the recombined polynucleotide. Polynucleotides made by this process, and modified yeast that contain the modified polynucleotides, are also provided.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: April 11, 2023
    Assignee: New York University
    Inventors: Jef Boeke, Yi Wu
  • Patent number: 11618928
    Abstract: The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect broth DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: April 4, 2023
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Omar Abudayyeh, James Joseph Collins, Jonathan Gootenberg, Feng Zhang, Eric S. Lander, Daniel Neafsey, Angela Early
  • Patent number: 11613759
    Abstract: The present disclosure pertains to methods for delivering a compound into a cell comprising a cell wall, including passing a cell suspension through a constriction, wherein said constriction deforms the cell comprising a cell wall, thereby causing a perturbation of the cell such that the compound enters the cell, wherein said cell suspension is contacted with the compound.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: March 28, 2023
    Assignee: SQZ Biotechnologies Company
    Inventors: Armon R. Sharei, Howard Bernstein, Jonathan B. Gilbert
  • Patent number: 11608519
    Abstract: Embodiments disclosed herein include devices, methods, and systems for direct, selective, and sensitive detection of single-stranded and double-stranded target DNA sequences from various sources using a Cas12a protein. When activated by binding a target DNA sequence, the Cas12a cleaves a tether releasing a reporter molecule that may then be detected. In some embodiments, the systems, methods, and devices may include a filter or membrane that may help to separate the tethered and untethered reporter molecules. These devices, systems, and techniques allow a user to rapidly process samples that may contain the target DNA, without needing to amplify the target sequences. These devices and methods may be used to assay a wide variety of samples and target DNA sources, for the presence or absence of target DNA sequences. Compositions and kits, useful in practicing these methods, for example detecting a target DNA in a biological sample, are also described.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: March 21, 2023
    Assignee: Tokitae LLC
    Inventors: Ted A. Baughman, Damian Madan, Eric Nalefski, Anne-Laure M. Le Ny
  • Patent number: 11600361
    Abstract: Disclosed herein are compositions, systems and methods related to sequence assembly, such as nucleic acid sequence assembly of single reads and contigs into larger contigs and scaffolds through the use of read pair sequence information, such as read pair information indicative of nucleic acid sequence phase or physical linkage.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: March 7, 2023
    Assignee: Dovetail Genomics, LLC
    Inventors: Nicholas H. Putnam, Jonathan C. Stites, Brandon J. Rice
  • Patent number: 11591581
    Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a SIN CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing SIN CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: February 28, 2023
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Feng Zhang, Beverly Davidson, Chie-Yu Lin, Edgardo Rodriguez
  • Patent number: 11591592
    Abstract: This invention relates to compositions of matter, methods, modules and automated, end-to-end closed instruments for automated mammalian cell growth, reagent bundle creation and mammalian cell transfection followed by nucleic acid-guided nuclease editing in live mammalian cells. The disclosed compositions and method entail making “reagent bundles” comprising many (hundreds of thousands to millions) clonal copies of an editing cassette and delivering or co-localizing the reagent bundles with live mammalian cells such that the editing cassettes edit the cells and the edited cells continue to grow.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: February 28, 2023
    Assignee: Inscripta, Inc.
    Inventors: Phillip Belgrader, Nathan Bade, Christian Siltanen, Aamir Mir, Xi-Jun Chen, Janine Mok, Burak Dura, Bruce Chabansky, David Stumbo, Eric Smith, Jorge Bernate
  • Patent number: 11584931
    Abstract: Provided are methods and compositions for generating a deletion library, and methods and compositions for generating and identifying a defective interfering particle (DIP). Also provided are transposon cassettes. A subject method can include: inserting a transposon cassette comprising a target sequence for a sequence specific DNA endonuclease into a population of circular target DNAs to generate a population of transposon-inserted circular target DNAs; contacting the population of transposon-inserted circular target DNAs with the sequence specific DNA endonuclease to generate a population of cleaved linear target DNAs; contacting the population of cleaved linear target DNAs with one or more exonucleases to generate a population of deletion DNAs; and circularizing the deletion DNAs to generate a library of circularized deletion DNAs. The population of circular target DNAs can include viral genomic DNA. Also provided are human immunodeficiency virus (HIV) deletion mutants, e.g.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 21, 2023
    Assignees: The J. David Gladstone Institutes, The Regents of the University of California
    Inventors: Leor S. Weinberger, Timothy J. Notton